A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
Status:
Recruiting
Trial end date:
2022-02-02
Target enrollment:
Participant gender:
Summary
This will be a 2 stage study in which Stage 1 will evaluate the safety of AGN-242428 and
AGN-231868, how well they are tolerated and how they move through the body when administered.
After the sponsor's determination of adequate safety and tolerability of the interventions in
Stage 1, Stage 2 will begin. Stage 2 will also evaluate the safety and tolerability of
AGN-242428 and AGN-231868, how effective they are in treating dry eye disease and assess the
plasma and tear exposure of both ophthalmic solutions.